Rituximab-abbs (Truxima) is the only biosimilar to the reference product rituximab (Rituxan).
The study warned that, with 74 million children in the United States, PICU resources could face concerning strain from COVID-19.
A new study evaluated methods of improving heart function in individuals with type 2 diabetes.
A case report from NYU Langone Health assessed the use of both urgent and non-urgent telemedicine visits.
Officials with the FDA have issued an emergency use authorization for remdesivir (Gilead Sciences) for the treatment of suspected or laboratory-confirmed coronavirus disease 2019 (COVID-19) in hospitalized adults and children.
Here's a roundup of this week's coronavirus-related news.
In part 2 of our interview, Aman Brar, chief executive officer of Jobvite, discussed with Drug Topics® how recruiting software is transforming the hiring process during the coronavirus disease 2019 pandemic.
In-depth interviews from 59 women living with HIV revealed that many women preferred long-acting injectable antiretroviral therapy for its convenience, privacy, and perceived effectiveness.
Officials with the FDA approved niraparib (Zejula, GlaxoSmithKline), a once-daily, oral monotherapy, for the first-line maintenance treatment of platinum-responsive advanced ovarian cancer regardless of biomarker status.
Americans are increasingly concerned about drug shortages due to the coronavirus disease 2019 (COVID-19) pandemic, according to a new survey by prescription savings service SingleCare.